Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: News Bites Pty Limited
|
$5.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Dr. Reddy's Laboratories Limited Announces Launch Of Quetiapine Fumarate Tablets
Dr. Reddy's Laboratories Limited announced that it has launched Quetiapine fumarate tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg), a bioequivalent generic version of SEROQUEL tablets in the US market on March 27, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Quetiapine fumarate tablets. The SEROQUEL brand had U.S. sales of approximately $4.6 billion for the recent twelve months ending December 2011 according to IMS Health. Dr. Reddy’s Quetiapine fumarate tablets in 25 mg and 50 mg are available in 100 and 500 count bottle sizes, 100 mg, 200 mg and 400 mg are available in 100 count bottle sizes and 300 mg is available in 60 count bottle sizes.
Latest Developments for Dr.Reddy's Laboratories Ltd
Latest Key Developments in Pharmaceuticals
- Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Announces Changes of General Manager
- Merck & Co Inc Announces $5 Billion Accelerated Share Repurchase
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Drug regulator to probe Ranbaxy Laboratories Ltd's records, approvals in India-Business Standard
- Share this
- Link this
- Digg this


Follow Reuters